Scarica l'app Stockscreener
2.58
9.15%
-0.26
Dopo l'orario di chiusura:
2.56
-0.02
-0.78%
Precedente Chiudi:
$2.84
Aprire:
$2.9
Volume 24 ore:
118.77K
Relative Volume:
0.18
Capitalizzazione di mercato:
$5.86M
Reddito:
-
Utile/perdita netta:
$-22.71M
Rapporto P/E:
-0.2203
EPS:
-11.71
Flusso di cassa netto:
$-18.24M
1 W Prestazione:
-23.89%
1M Prestazione:
-41.76%
6M Prestazione:
-82.32%
1 anno Prestazione:
-95.55%
Intervallo 1D:
$2.57
$2.92
Intervallo di 1 settimana:
$2.51
$3.4153
Portata 52W:
$2.51
$63.00
Genprex Inc Stock (GNPX) Company Profile
Nome
Genprex Inc
Settore
Industria
Telefono
512-537-7997
Indirizzo
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Confronta GNPX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
2.58 | 6.45M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-01-26 | Iniziato | National Securities | Buy |
| 2019-04-29 | Iniziato | Noble Capital Markets | Outperform |
Genprex Inc Borsa (GNPX) Ultime notizie
MSN Money - MSN
Genprex Secures U.S. Patent for Reqorsa® Therapy - MSN
Genprex Inc Stock Analysis and ForecastSector-Based Investing & High Yield Market Growth - earlytimes.in
Will Genprex Inc. (2DE0) stock recover faster than industry2025 Analyst Calls & Risk Managed Investment Signals - Newser
Is Genprex Inc. (2DE0) stock undervalued after correctionJuly 2025 PreEarnings & Risk Controlled Daily Trade Plans - Newser
Is Genprex Inc. stock cheap at current valuationWeekly Profit Report & Community Driven Trade Alerts - Newser
Congressman Buys Shares Of Small Cap Lift Truck Company You've Probably Never Heard Of - Benzinga
Can Genprex Inc. (2DE0) stock reach $200 price targetEarnings Growth Summary & Entry and Exit Point Strategies - Newser
Get in on Genprex Inc’s (GNPX) buy-in window today! - setenews.com
Why Genprex Inc. stock remains on buy listsWeekly Profit Summary & Fast Gaining Stock Reports - Newser
Genprex, Inc. Stock (GNPX) Opinions on Recent Preclinical Data Release - Quiver Quantitative
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules - Aktiellt
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules - Aktiellt
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire) - Aktiellt
Can Genprex Inc. stock beat market expectations this quarterMarket Activity Recap & Stepwise Entry/Exit Trade Alerts - BỘ NỘI VỤ
Taking the lead: Genprex Inc (GNPX) - Setenews
How Genprex Inc. (2DE0) stock reacts to new regulations2025 Market Trends & Daily Volume Surge Signals - BỘ NỘI VỤ
Genprex regains Nasdaq bid price compliance, receives equity extension By Investing.com - Investing.com Australia
Genprex regains Nasdaq bid price compliance, receives equity extension - Investing.com
Genprex keeps Nasdaq listing with bid-price fix, equity waiver granted - Stock Titan
Genprex reports phase 1 data for lung cancer gene therapy By Investing.com - Investing.com Nigeria
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Tria - GuruFocus
Genprex (GNPX) Shares Positive Acclaim-1 Trial Data for Lung Can - GuruFocus
Genprex reports phase 1 data for lung cancer gene therapy - Investing.com
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer - PR Newswire
Genprex files prospectus supplement for up to $75 million at-the-market offering By Investing.com - Investing.com Australia
Genprex files prospectus supplement for up to $75 million at-the-market offering - Investing.com Australia
Genprex Inc. (GNPX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Genprex Announces $75 Million Stock Offering - MSN
[S-1] Genprex, Inc. Files IPO Registration Statement | GNPX SEC FilingForm S-1 - Stock Titan
Genprex, Inc. Announces $75 Million Stock Offering - TradingView
[8-K] Genprex, Inc. Reports Material Event | GNPX SEC FilingForm 8-K - Stock Titan
Can Genprex Inc. (2DE0) stock sustain revenue momentumWeekly Stock Summary & Safe Swing Trade Setup Alerts - newser.com
How Genprex Inc. stock benefits from tech adoption2025 Valuation Update & Reliable Volume Spike Trade Alerts - newser.com
Is Genprex Inc. stock attractive for retirement portfoliosJuly 2025 Breakouts & High Conviction Trade Alerts - newser.com
Why Genprex Inc. (2DE0) stock attracts wealthy investorsPortfolio Gains Summary & Fast Gain Swing Trade Alerts - newser.com
Is Genprex Inc. (2DE0) stock at risk of policy regulationWeekly Profit Report & Expert Approved Momentum Trade Ideas - newser.com
Will Genprex Inc. (2DE0) stock outperform global peersJuly 2025 Gainers & Consistent Growth Equity Picks - newser.com
Published on: 2025-11-19 22:26:30 - newser.com
Genprex Inc Azioni (GNPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):